Avoro Capital Advisors’s Alnylam Pharmaceuticals ALNY Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q3 | – | Sell |
-400,000
| Closed | -$97.2M | – | 37 |
|
|
2024
Q2 | $97.2M | Buy |
400,000
+100,000
| +33% | +$24.3M | 1.29% | 19 |
|
|
2024
Q1 | $44.8M | Sell |
300,000
-811,111
| -73% | -$121M | 0.52% | 33 |
|
|
2023
Q4 | $213M | Buy |
1,111,111
+100,000
| +10% | +$19.1M | 2.94% | 15 |
|
|
2023
Q3 | $179M | Sell |
1,011,111
-93,889
| -8% | -$16.6M | 2.79% | 13 |
|
|
2023
Q2 | $210M | Hold |
1,105,000
| – | – | 2.85% | 13 |
|
|
2023
Q1 | $221M | Hold |
1,105,000
| – | – | 3.28% | 11 |
|
|
2022
Q4 | $263M | Hold |
1,105,000
| – | – | 3.92% | 10 |
|
|
2022
Q3 | $221M | Sell |
1,105,000
-255,000
| -19% | -$51M | 4.09% | 11 |
|
|
2022
Q2 | $198M | Buy |
1,360,000
+60,000
| +5% | +$8.75M | 3.92% | 11 |
|
|
2022
Q1 | $212M | Buy |
1,300,000
+225,000
| +21% | +$36.7M | 3.88% | 10 |
|
|
2021
Q4 | $182M | Buy |
1,075,000
+225,000
| +26% | +$38.2M | 3.1% | 10 |
|
|
2021
Q3 | $160M | Sell |
850,000
-150,000
| -15% | -$28.3M | 2.52% | 12 |
|
|
2021
Q2 | $170M | Buy |
+1,000,000
| New | +$170M | 2.95% | 10 |
|
|
2018
Q3 | – | Sell |
-700,100
| Closed | -$69M | – | 44 |
|
|
2018
Q2 | $69M | Buy |
+700,100
| New | +$69M | 2.65% | 13 |
|